130 related articles for article (PubMed ID: 37459571)
1. Improved Outcome for ALL by Prolonging Therapy for
Pieters R; de Groot-Kruseman H; Fiocco M; Verwer F; Van Overveld M; Sonneveld E; van der Velden V; Beverloo HB; Bierings M; Dors N; de Haas V; Hoogerbrugge P; Van der Sluis I; Tissing W; Veening M; Boer J; Den Boer M
J Clin Oncol; 2023 Sep; 41(25):4130-4142. PubMed ID: 37459571
[TBL] [Abstract][Full Text] [Related]
2. ETV6/RUNX1-positive childhood acute lymphoblastic leukemia in China: excellent prognosis with improved BFM protocol.
Wang Y; Zeng HM; Zhang LP
Ital J Pediatr; 2018 Aug; 44(1):94. PubMed ID: 30115129
[TBL] [Abstract][Full Text] [Related]
3. Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol.
Gandemer V; Chevret S; Petit A; Vermylen C; Leblanc T; Michel G; Schmitt C; Lejars O; Schneider P; Demeocq F; Bader-Meunier B; Bernaudin F; Perel Y; Auclerc MF; Cayuela JM; Leverger G; Baruchel A;
Haematologica; 2012 Nov; 97(11):1743-50. PubMed ID: 22580999
[TBL] [Abstract][Full Text] [Related]
4. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group.
Pieters R; de Groot-Kruseman H; Van der Velden V; Fiocco M; van den Berg H; de Bont E; Egeler RM; Hoogerbrugge P; Kaspers G; Van der Schoot E; De Haas V; Van Dongen J
J Clin Oncol; 2016 Aug; 34(22):2591-601. PubMed ID: 27269950
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and prognostic factors of the chemotherapy regimen of CCLG-ALL-2008 on pediatric acute lymphoblastic leukemia with ETV6-RUNX1 rearrangement].
Liu F; Chen XJ; Guo Y; Yang WY; Chen X; Zhang XY; Zhang RR; Ren YY; Zhu XF
Zhonghua Xue Ye Xue Za Zhi; 2020 Nov; 41(11):896-902. PubMed ID: 33333691
[No Abstract] [Full Text] [Related]
6. Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study.
Yeoh AEJ; Lu Y; Chin WHN; Chiew EKH; Lim EH; Li Z; Kham SKY; Chan YH; Abdullah WA; Lin HP; Chan LL; Lam JCM; Tan PL; Quah TC; Tan AM; Ariffin H
J Clin Oncol; 2018 Sep; 36(26):2726-2735. PubMed ID: 30044693
[TBL] [Abstract][Full Text] [Related]
7. [Report of Chinese Children's Cancer Group acute lymphoblastic leukemia 2015 multicenter study].
Chinese Children′s Cancer Group Acute Lymphoblastic Leukemia 2015 Study Group
Zhonghua Er Ke Za Zhi; 2022 Oct; 60(10):1002-1010. PubMed ID: 36207846
[No Abstract] [Full Text] [Related]
8. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
9. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
[TBL] [Abstract][Full Text] [Related]
10. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
[TBL] [Abstract][Full Text] [Related]
11. ETV6-RUNX1-positive childhood acute lymphoblastic leukemia: improved outcome with contemporary therapy.
Bhojwani D; Pei D; Sandlund JT; Jeha S; Ribeiro RC; Rubnitz JE; Raimondi SC; Shurtleff S; Onciu M; Cheng C; Coustan-Smith E; Bowman WP; Howard SC; Metzger ML; Inaba H; Leung W; Evans WE; Campana D; Relling MV; Pui CH
Leukemia; 2012 Feb; 26(2):265-70. PubMed ID: 21869842
[TBL] [Abstract][Full Text] [Related]
12. Differing Outcomes of Patients with High Hyperdiploidy and ETV6-RUNX1 Rearrangement in Korean Pediatric Precursor B Cell Acute Lymphoblastic Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B
Cancer Res Treat; 2021 Apr; 53(2):567-575. PubMed ID: 33070555
[TBL] [Abstract][Full Text] [Related]
13. [Clinical features and prognostic analysis of testicular relapse in pediatric acute lymphoblastic leukemia].
Wang N; Gao YY; Qi BQ; Ruan M; Lyu H; Zhang XY; Zhang RR; Liu TF; Chen YM; Zou Y; Guo Y; Yang WY; Zhang L; Zhu XF; Chen XJ
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):262-267. PubMed ID: 38378289
[No Abstract] [Full Text] [Related]
14. Outcome and Prognostic Factors for
Lee JW; Kim SK; Jang PS; Chung NG; Jeong DC; Kim M; Cho B; Kim HK
Cancer Res Treat; 2017 Apr; 49(2):446-453. PubMed ID: 27506214
[TBL] [Abstract][Full Text] [Related]
15. Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia.
Sutton R; Shaw PJ; Venn NC; Law T; Dissanayake A; Kilo T; Haber M; Norris MD; Fraser C; Alvaro F; Revesz T; Trahair TN; Dalla-Pozza L; Marshall GM; O'Brien TA
Br J Haematol; 2015 Feb; 168(3):395-404. PubMed ID: 25312094
[TBL] [Abstract][Full Text] [Related]
16. Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Schrappe M; Bleckmann K; Zimmermann M; Biondi A; Möricke A; Locatelli F; Cario G; Rizzari C; Attarbaschi A; Valsecchi MG; Bartram CR; Barisone E; Niggli F; Niemeyer C; Testi AM; Mann G; Ziino O; Schäfer B; Panzer-Grümayer R; Beier R; Parasole R; Göhring G; Ludwig WD; Casale F; Schlegel PG; Basso G; Conter V
J Clin Oncol; 2018 Jan; 36(3):244-253. PubMed ID: 29148893
[TBL] [Abstract][Full Text] [Related]
17. IKZF1 deletion is associated with a poor outcome in pediatric B-cell precursor acute lymphoblastic leukemia in Japan.
Asai D; Imamura T; Suenobu S; Saito A; Hasegawa D; Deguchi T; Hashii Y; Matsumoto K; Kawasaki H; Hori H; Iguchi A; Kosaka Y; Kato K; Horibe K; Yumura-Yagi K; Hara J; Oda M;
Cancer Med; 2013 Jun; 2(3):412-9. PubMed ID: 23930217
[TBL] [Abstract][Full Text] [Related]
18. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.
Buitenkamp TD; Izraeli S; Zimmermann M; Forestier E; Heerema NA; van den Heuvel-Eibrink MM; Pieters R; Korbijn CM; Silverman LB; Schmiegelow K; Liang DC; Horibe K; Arico M; Biondi A; Basso G; Rabin KR; Schrappe M; Cario G; Mann G; Morak M; Panzer-Grümayer R; Mondelaers V; Lammens T; Cavé H; Stark B; Ganmore I; Moorman AV; Vora A; Hunger SP; Pui CH; Mullighan CG; Manabe A; Escherich G; Kowalczyk JR; Whitlock JA; Zwaan CM
Blood; 2014 Jan; 123(1):70-7. PubMed ID: 24222333
[TBL] [Abstract][Full Text] [Related]
19. [Effect of increasing the intensity of chemotherapy on the prognosis of acute lymphoblastic leukemia in children with IKZF1 deletion].
Zheng YZ; Li J; LE SH; Zheng H; Hua XL; Chen ZS; Hu JD
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Jul; 21(7):690-695. PubMed ID: 31315770
[TBL] [Abstract][Full Text] [Related]
20. Intensive treatment of children with acute lymphoblastic leukemia according to ALL-BFM-86 without cranial radiotherapy: results of Dutch Childhood Leukemia Study Group Protocol ALL-7 (1988-1991).
Kamps WA; Bökkerink JP; Hählen K; Hermans J; Riehm H; Gadner H; Schrappe M; Slater R; van den Berg-de Ruiter E; Smets LA; de Vaan GA; Weening RS; van Weerden JF; van Wering ER; den der Does-van den Berg A
Blood; 1999 Aug; 94(4):1226-36. PubMed ID: 10438710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
